ROLLINS INC (ROL) vs. DENTSPLY SIRONA Inc. (XRAY) Stock Comparison & Valuation | Edwyn

Edwyn

Edwyn Search companies, tickers, CIKs…⌘K

ROLLINS INC (ROL) vs. DENTSPLY SIRONA Inc. (XRAY) Stock Comparison & Valuation | Edwyn

Updated 2026-07-22 13:43 UTC

This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.

ROL screens as materially stronger operationally and financially than XRAY, and its current price looks justified relative to its superior growth, profitability, and balance-sheet quality despite a premium valuation multiple.

Actionable Takeaway

If you believe ROL can sustain double-digit growth and high ROIC while maintaining its low leverage, then hold or accumulate ROL because its premium valuation is supported by materially better profitability and balance-sheet quality than XRAY.

The valuation gap is extreme on the provided P/S-based framework: ROL’s current price of $44.59 versus an implied price of $5.81 suggests an -87.0% downside if XRAY’s multiple were applied mechanically. That gap is consistent with ROL’s much stronger fundamentals, while XRAY’s distressed profitability and leverage make its low trading multiples less comparable.

Supporting Metrics

Key Risks

ROL valuation risk: P/S of 5.7x leaves little room for disappointment if growth slows.
ROL quality risk: Piotroski F-Score of 5/9 is only mid-range, not best-in-class.
Comparison risk: XRAY’s negative earnings and 125.7x Net Debt/EBITDA make it a weak valuation anchor for relative pricing.